Our summary: national advocacy actions from January to April 2026
In this blog, we share a summary of the initiatives we are carrying out at the national level to influence public policy, build partnerships with organizations, strengthen our community networks, and advocate for a rights-based, gender-sensitive, and intersectional approach across the various are
https://www.tedic.org/en/our-summary-national-advocacy-actions-from-january-to-april-2026/
Our summary: International advocacy efforts from January to April 2026
As we do every year, TEDIC is presenting a quarterly summary of our international advocacy efforts, in accordance with our internal transparency policy, which we have followed since 2015. Find out everything we’ve been doing on the international stage so far this year
https://www.tedic.org/en/our-summary-international-advocacy-efforts-from-january-to-april-2026/
I do an informal survey of cars in car parks when I go there.
Basically looking for green flashes on the number plate, = EV and older ones before that identifier came in.
In the spaces opposite the coffee shop (I commonly walk to) over 3 years we have gone from rare sightings to very often one EV and sometimes 2.
DÉMARCHES CRÉATIVES Expérimentez plusieurs laboratoires articulant expression artistique et citoyenne. Objectifs Découvrir et comprendre ce qui constitue la démarche créative ( notamment en CEC ) Apprendre à élaborer vos propres démarches créatives adaptées au contexte, aux paramètres des champs d’action,
Congratulations to Thomas Beneteau for his in-depth analysis of the #incidence and #duration of #HPV infections in young women using multivariate #Cox regression models with #frailty effects.
This work based on the #PAPCLEAR #cohort in #Montpellier and the #EVOLPROOF project is now published in #InfectiousDiseases.
#DM for a #PDF version until we can opt for #GreenOpenAccess.
Objective To provide a baseline comparative assessment of the main epidemiological features of prostate cancer in European populations as background for the proposed EU screening initiatives. Design Population based study. Setting 26 European countries, 19 in the EU, 1980-2017. National or subnational incidence data were extracted from population based cancer registries from the International Agency for Research on Cancer’s Global Cancer Observatory, and mortality data from the World Health Organization. Population Men aged 35-84 years from 26 eligible countries. Results Over the past decades, incidence rates for prostate cancer varied markedly in both magnitude and rate of change, in parallel with temporal variations in prostate specific antigen testing. The variation in incidence across countries was largest around the mid-2000s, with rates spanning from 46 (Ukraine) to 336 (France) per 100 000 men. Thereafter, incidence started to decline in several countries, but with the latest rates nevertheless remaining raised and increasing again in the most recent quinquennium in several countries. Mortality rates during 1980-2020 were much lower and less variable than incidence rates, with steady declines in most countries and lesser temporal differences between countries. Overall, the up to 20-fold variation in prostate cancer incidence contrasts with a corresponding fivefold variation in mortality. Also, the inverse U-shape of the age specific curves for incidence contrasted with the mortality pattern, which increased progressively with age. The difference between the highest and lowest incidence rates across countries ranged from 89.6 per 100 000 men in 1985 to 385.8 per 100 000 men in 2007, while mortality rates across countries ranged from 23.7 per 100 000 men in 1983 to 35.6 per 100 000 men in 2006. Conclusions The epidemiological features of prostate cancer presented here are indicative of overdiagnosis varying over time and across populations. Although the results are ecological in nature and must be interpreted with caution, they do support previous recommendations that any future implementation of prostate cancer screening must be carefully designed with an emphasis on minimising the harms of overdiagnosis. All data used for analyses are available from the International Agency for Research on Cancer at <http://ci5.iarc.fr> and the World Health Organization at <https://www.who.int/data/data-collection-tools/who-mortality-database>.
#Russia sees sharp rise in #COVID cases, https://ura.news/news/1052812899
"The #incidence of COVID has increased by 20% in Russia over the past week," the TASS task force reported, adding that the number of hospitalizations has increased by 52.3%.
#COVID19 cases in #Russia have increased by almost 30 percent in a week, RIA: https://ria.ru/20240806/koronavirus-1964351206.html?in=l
"The #incidence #rate of the new #coronavirus infection over the past week per 100 thousand people was 5.43 & increased by 28.2% compared to the previous week. An increase in the incidence rate was noted in 58 subjects of the Russian Federation, including in 14 regions more than the national average," the report says.
The atomic bombing of Hiroshima, Japan, by the United States in August 1945 was not only devastating at the time, resulting in the deaths of hundreds of thousands of people, but it has had long-standing impacts to the present day, particularly the elevated incidence of cancer from radiation.
Biphasic #MERS-CoV #Incidence in Nomadic #Dromedaries with Putative #Transmission to #Humans, Kenya, 2022–2023, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/3/23-1488_article
-- MERS-CoV is endemic in dromedaries in Africa, but camel-to-human transmission is limited. Sustained 12-mos sampling of dromedaries in a #Kenya abattoir hub showed biphasic MERS-CoV incidence; peak detections occurred in Oct 22 and Febr 23. Dromedary-exposed abattoir workers (7/48) had serologic signs of previous MERS-CoV exposure.
TEDIC
a fading echo
Jean-Luc Urbain
Ecology & Evolution of Health
Christophe Neff
Giuseppe Michieli
Matt Willemsen